Harmony Biosciences' CFO Sells All of Her Insider Shares, Worth $752,800
Key Points
Sandip Kapadia sold 20,961 shares for a transaction value of approximately $752,800 on Jan. 15, 2026.
Harmony Biosciences reported strong Q3 2025 earnings and expects to generate $1 billion in revenue from one of its top products.
- These 10 stocks could mint the next wave of millionaires ›
Sandip Kapadia, Chief Financial Officer of Harmony Biosciences (NASDAQ:HRMY), executed an open-market sale of 20,961 directly held shares on Jan. 15, 2026, fully exiting direct equity ownership, according to a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 20,961 |
| Transaction value | ~$752,800 |
| Post-transaction shares (direct) | 0 |
Transaction value based on SEC Form 4 weighted average purchase price ($35.92).
Key questions
- How significant was this transaction in the context of Kapadia’s historical selling activity?
This sale fully liquidated Kapadia’s remaining direct position, following a series of prior dispositions over the past year that cumulatively reduced direct holdings from 72,948 shares to zero. - How does the transaction price compare to the market price at the time of the sale?
The weighted-average sale price was around $35.92 per share, slightly below the market close of $36.41 on Jan. 15, 2026, and below the current share price of $36.62 as of Jan. 31, 2026.
Company overview
| Metric | Value |
|---|---|
| Price (as of Jan. 31, 2026) | $35.52 |
| Market capitalization | $2.1 billion |
| Revenue (TTM) | $825.94 million |
| Net income (TTM) | $185.68 million |
Company snapshot
Harmony Biosciences is a U.S.-based biopharmaceutical company specializing in the development and commercialization of therapies for rare neurological diseases. One of its most successful therapies is WAKIX, a pharmaceutical product that addresses narcolepsy.
What this transaction means for investors
The shares Kapadia sold were part of a Rule 10b5-1 trading plan, so they were planned in advance, and we can’t truly determine why she decided to fully exit from her equity in the company. But for investors, Harmony Biosciences’ stock looks very promising, as its financials have been strong so far in FY 2025, including a strong Q3 2025, when it posted its highest net income since Q3 2022.
In its preliminary Q4 2025 revenue report in January 2026, the company stated that it expects to achieve over $1 billion in revenue from WAKIX alone by the end of 2026, as Harmony Biosciences holds an exclusive license to the medication, and it has been highly successful.
The company also has other medications that have advanced to later stages of development, which are estimated to generate enough revenue for the pharmaceutical producer to operate well into 2040. With a 10% increase in 2025, strong financial results, and an outlook, HRMY has a strong case as an ideal biomedical stock investment.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 942%* — a market-crushing outperformance compared to 196% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
See the stocks »
*Stock Advisor returns as of January 31, 2026.
Adé Hennis has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
